Scott Blumberg Sells 1,521 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 1,521 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $36,534.42. Following the completion of the sale, the chief financial officer directly owned 146,600 shares of the company’s stock, valued at $3,521,332. The trade was a 1.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total transaction of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total transaction of $24,750.00.

CeriBell Stock Down 2.1%

Shares of NASDAQ CBLL opened at $23.45 on Thursday. The stock has a fifty day moving average price of $19.89 and a 200 day moving average price of $19.30. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $25.33. The company has a market cap of $900.01 million, a P/E ratio of -13.32 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The company had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. Research analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Key Headlines Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: BTIG Research raised its price target for CBLL to $30 from $28 and reiterated a Buy rating. Canaccord Genuity also increased its target to $26, while the overall analyst consensus remains “Moderate Buy.”
• Positive Sentiment: Several institutional investors recently increased or initiated positions in CeriBell, including Caitong International Asset Management, CWM LLC, Tower Research Capital and Legal & General, although the dollar values of these holdings remain modest.
• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares worth about $307,000. The executives retained substantial positions, and the filings identified tax withholding after equity vesting as the reason for the sales. CeriBell insider transaction report
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from August 10. The zero-day days-to-cover figure offers little useful information and may reflect anomalous reporting.
• Negative Sentiment: CeriBell’s latest quarterly results were mixed: revenue of $28.10 million exceeded expectations, but adjusted earnings of negative $0.51 per share missed the consensus estimate of negative $0.47. The company remains unprofitable, with analysts expecting a full-year loss of approximately $1.96 per share.
• Negative Sentiment: The coordinated selling by multiple senior executives may create a modest overhang, particularly with the shares near their 52-week high. The impact is tempered by the sales’ stated tax-related purpose and the executives’ continued ownership.

Institutional Trading of CeriBell

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of CeriBell in the 2nd quarter worth approximately $37,657,000. Bank of New York Mellon Corp raised its position in shares of CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after acquiring an additional 1,162,200 shares in the last quarter. KCM Capital Inc bought a new position in CeriBell during the fourth quarter worth $21,930,000. TimesSquare Capital Management LLC bought a new position in CeriBell during the second quarter worth $15,182,000. Finally, Royce & Associates LP acquired a new position in CeriBell in the fourth quarter worth $11,695,000.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on CBLL. BTIG Research lifted their price objective on shares of CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group raised their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and a consensus price target of $22.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.